75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
On top of the newly approved lung disorder pill Brinsupri, which Insmed expects will achieve blockbuster sales this year, the New Jersey company has ...
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ...
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying ...
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a ...
Global warming has accelerated in a "statistically significant" way since 2015, according to a study published by the Potsdam Institute for Climate Impact Research (PIK)."Over the past 10 years, the ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Today, the Institute for Energy Research released new analysis on data centers and electricity rates. The report, Have ...
Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant data of the acquired lead, ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results